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Human leukocyte antigen (HLA)
Chagas disease is a major neglected tropical disease caused by persistent chronic infection with the protozoan
parasite Trypanosoma cruzi. An estimated 8 million people are infected with T. cruzi, however only 2 drugs are approved
for treatment and no vaccines are available. Thus there is an urgent need to develop vaccines and new drugs to
prevent and treat Chagas disease. In this work, we identify T cell targets relevant for human infection with T. cruzi. The
trans-sialidase (TS) gene family is a large family of homologous genes within the T. cruzi genome encoding over 1,400
members. There are 12 highly conserved TS gene family members which encode enzymatically active TS (functional TS;
F-TS), while the remaining TS family genes are less conserved, enzymatically inactive and have been hypothesized to be
involved in immune evasion (non-functional TS; NF-TS). We utilized immunoinformatic tools to identify HLA-A2-
restricted CD8C T cell epitopes conserved within F-TS family members and NF-TS gene family members. We also
utilized a whole-genome approach to identify T cell epitopes present within genes which have previously been shown
to be expressed in life stages relevant for human infection (Non-TS genes). Thirty immunogenic HLA-A2-restricted CD8C
T cell epitopes were identiﬁed using IFN-g ELISPOT assays after vaccination of humanized HLA-A2 transgenic mice with
mature dendritic cells pulsed with F-TS, NF-TS, and Non-TS peptide pools. The immunogenic HLA-A2-restricted T cell
epitopes identiﬁed in this work may serve as potential components of an epitope-based T cell targeted vaccine for
Chagas disease.
Over 1 billion people are infected with neglected tropical dis-
eases (NTD), which predominantly affect poor people in devel-
oping countries.1 Chagas disease is one such NTD, caused by
chronic infection with the protozoan parasite Trypanosoma cruzi.
An estimated 8 million people are infected with this tropical par-
asite resulting in thousands of deaths per year.2 Due to emigra-
tion, Chagas disease is now a public health concern in many
regions and countries throughout the world. For example,
300,000 people in the United States are estimated to be infected
with T. cruzi.3 Up to 40% of infected individuals go on to
develop clinical manifestations associated with chronic Chagas
disease which include both cardiac (cardiomyopathy) and gastro-
intestinal abnormalities (megaesophogus and megacolon).2 There
are currently no vaccines available for prevention of T. cruzi
infection. Drugs including nifurtimox and benznidazole have
proven effective at treating T. cruzi infection, but both are associ-
ated with many adverse reactions and are not well tolerated in a
large number of patients.4 However, the utilization of these drugs
has challenged and disproven the belief that the underlying cause
of chronic Chagas disease is autoimmunity.5-9 In recent years
there have been significant efforts to develop prophylactic and
therapeutic vaccines as well as new drugs for the prevention and
treatment of Chagas disease.
T. cruzi is primarily transmitted to humans by insect-derived
metacyclic trypomastigotes (MT) present in the excreta of triato-
mine (reduviid) insects.2 Epimastigotes present in the insect mid-
gut differentiate into highly infectious MT with migration into
the hindgut. Triatomines ingest blood from a variety of mam-
mals, and quickly begin processing the blood meal. MT are
flushed from the hindgut during the defecation process and are
capable of initiating host infection through breaks in the skin
(i.e., the insect bite site), or by entry through mucosal routes
such as the eyes or mouth. Once inside the cell, MT differentiate
into amastigotes (AMA) which are the only dividing parasite
form present in humans. After several rounds of division, AMA
differentiate into blood-form trypomastigotes (BFT) which are
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released upon cell lysis. These BFT can infect local cells, other
cells in the body after dissemination through the circulation, or
new insects. Proteins expressed in parasite life stages relevant for
human infection (MT, AMA, and BFT) are worth consideration
as potential targets of vaccine-induced immunity in humans and
other susceptible mammals.
Immunity to T. cruzi infection is multifaceted involving a
variety of cell types. T. cruzi infection induces robust B cell (anti-
body) responses in both mice and humans. However, antibody-
secreting B cells may function more importantly to prevent
CD8C T cell exhaustion during chronic T. cruzi infection as we
have recently described.10 Both CD4C and CD8C T cells are crit-
ical in the development of protective immunity.11-14 We recently
demonstrated that dendritic cell vaccines pulsed with only a sin-
gle CD4C T cell epitope and a single CD8C T cell epitope from
T. cruzi trans-sialidase can protect mice against highly virulent
T. cruzi challenge (manuscript submitted). CD4C T cells are
important in the priming of parasite-specific immunity, whereas
CD8C T cells are essential for effector function and parasite
clearance. Once immunity is generated, CD8C T cells alone can
protect mice against parasite challenge as shown in adoptive
transfer experiments.15 In humans infected with T. cruzi, vigor-
ous CD8C T cell responses have been reported.16-18 Further-
more, frequencies of parasite-specific CD8C IFN-g-producing T
cells inversely correlate with severity of Chagas disease progres-
sion.16 Therefore, it is essential that vaccines target the induction
of CD8C T cell responses to offer optimal protective immunity.
The overwhelming majority of studies investigating immunity
to T. cruzi infection are performed in mice. Murine models of T.
cruzi infection offer clear cut answers to basic science questions,
but may not be an effective proxy for studying human immune
responses. T cell responses are not only species specific, but also
MHC allele specific. Thus the specific peptides immunogenic in
one mouse strain will likely not be immunogenic in other strains
of mice or humans. Transgenic mice expressing human MHC
(human leukocyte antigen; HLA) are useful tools for identifying
T cell epitopes relevant for humans. Approximately 50% of
humans express MHC class I alleles which share similar binding
profiles and belong to the HLA-A2 supertype.19 T cell epitopes
immunogenic in HLA-A2 transgenic mice therefore have a high
likelihood of being immunogenic in many humans. The goal of
our work here is to identify HLA-A2-restricted CD8C T cell epit-
opes immunogenic in HLA-A2 transgenic mice that could help
facilitate translational Chagas vaccine development efforts.
Multi-epitope vaccines are being investigated for numerous
pathogens, including HIV, influenza, vaccinia, and others. While
whole proteins and partial proteins have several vaccine develop-
ment benefits in terms of antigen generation, testing, and scaling
up of production for human use, there are certain disadvantages
inherent in these types of vaccines. First, when choosing a single
protein or multiple single proteins as vaccine candidates, the sheer
number of T cell epitopes within these proteins is quite limited
(in terms of absolute number of epitopes capable of stimulating T
cells restricted by diverse HLA alleles expressed by all human pop-
ulations at risk). Generating multi-epitope vaccines allows one to
design and incorporate multiple highly immunogenic T cell
epitope that target known MHC alleles and supertypes. The
resulting multi-epitope vaccines can thus achieve robust
‘population coverage’ ensuring that the vaccines can elicit immune
responses in individuals with diverse HLA expression. Addition-
ally, within any protein there are sequences present which share
similarity between organisms (i.e., parasite and human). An
immunoinformatic vaccine design approach with a strategy in
place to identify and remove “self” homologous sequences allows
vaccinologists to eliminate any potential cause of vaccine-induced
autoimmunity or amplification of T regs involved in prevention
of autoimmunity. This is particularly relevant when designing
Chagas vaccines, as previous evidence suggests the disease is caused
at least in part by autoimmunity.
As described above, the genome of T. cruzi contains multiple
large gene families, and researchers have hypothesized that these
gene families may have evolved as a mechanism of immune eva-
sion.20 The largest T. cruzi gene family is the trans-sialidase (TS)
gene family. TS transfers sialic acid from host cells onto the para-
site surface – a process known to be important in parasite infectiv-
ity.21 While some studies have suggested the dampening of
immunity by TS family proteins, we and others have shown that
TS antigens are highly immunogenic in both mice and
humans.14,15,22,23, Immunization of multiple susceptible mouse
strains with TS vaccines expressing enzymatically active (func-
tional) TS antigens elicit robust T cell responses protective against
highly lethal systemic T. cruzi challenges. TS gene family mem-
bers are being pursued by multiple investigators as viable vaccine
candidates, however, the most relevant T cell epitopes for human
infection are unknown. One goal of our work described here is to
identify T cell targets restricted by a major human MHC I super-
type (HLA-A2) conserved within TS gene family members.
As shown in Figure 1A, nearly half of the 1,430 TS gene fam-
ily members are pseudogenes, and of the remaining 735 TS genes,
only 12 encode proteins with enzymatic activity.20,24,25 These 12
functional TS (F-TS) genes are highly homologous, sharing 75%
to over 90% sequence identity to the consensus T. cruzi TS
enzyme sequence (GenBank accession D50685). Conversely, the
723 non-functional TS (NF-TS) genes are much more diverse,
and largely of unknown function. In order to identify T cell epito-
pes conserved within F-TS and NF-TS gene sets, we employed a
2-staged approach using immunoinformatic tools developed by
EpiVax. First, the Conservatrix algorithm was used to identify 9-
mer and 10-mer peptides that are conserved within F-TS and NF-
TS gene families.26 Briefly, input protein sequences were parsed
into overlapping 9-mer or 10-mer frames where each frame over-
laps the last by 8 or 9 amino acids, respectively. Identical 9-mer
(or 10-mer) sequences were then grouped and sequences which
were 50% conserved among the 12 F-TS genes or expressed by
5% of NF-TS genes were collected. Second, the EpiMatrix algo-
rithm was used to screen the conserved sequences for predicted
MHC binding affinity with respect to a panel of 6 MHC class I
“supertype” alleles.26-28 For each amino acid in a given input
sequence, the EpiMatrix algorithm retrieves a position specific
binding coefficient. The individual coefficients are summed to
produce a raw EpiMatrix score. Raw scores are normalized with
respect to a large sample of randomly generated peptides.
www.tandfonline.com 2323Human Vaccines & Immunotherapeutics
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EpiMatrix scores 1.64, representing the top 5% of peptides,
have a high likelihood to bind to the represented MHC-I super-
type. Taken collectively the 6 HLA supertypes included in this
analysis cover >95% of the human population. Peptides predicted
to bind with HLA-A2 were checked for homology to known
human sequences using BlastP. After screening out human homo-
logues, the top 6 HLA-A2 binding peptides, for both the F-TS
and NF-TS gene sets, were selected for further study.
In addition to identifying potential CD8C T cell epitopes
within F-TS and NF-TS gene family members, we utilized a
‘whole genome approach’ to identify a more diverse set of T cell
epitopes as shown in Figure 1B. The genome and proteomes of
all 4 major life stages of T. cruzi were analyzed in 2005, and data
made available through the TriTrypDB.25 The 2,185 genes
expressed in life stages relevant for human infection (MT, AMA,
and BFT), according to mass spectrometry evidence, were gath-
ered for analysis utilizing tools on the TriTrypDB. Since secreted
proteins are more likely to be recognized by the mammalian
immune system because of delivery to the host cell cytoplasm, we
narrowed our strategy to include genes with predicted signal
sequences but without multiple predicted trans-membrane
domains or potential lipid attachment sites utilizing publicly
available tools (TriTrypDB, LipoP, Phobius, SignalP). The
amino acids sequences of 204 selected secreted proteins were
parsed into 9-mer frames and then each frame was scored for pre-
dicted MHC I binding to 6 major supertypes using EpiMatrix as
described above. We refer to epitopes predicted in this gene set as
Non-TS epitopes (since TS sequences were included in the other
gene set analyses and were thus excluded here). This diverse set of
epitopes included sequences from mucin-associated surface pro-
teins (MASP), gp63 surface proteases, cruzipain precursors, pitri-
lysin-like metalloproteases, and others.
We next developed a strategy involving peptide vaccination of
HLA-A2 transgenic mice to identify immunogenic CD8C T cell
epitopes rather than performing MHC binding assays which do
not confirm T cell reactivity. All animal studies were conducted
in AAALAC accredited facilities and were approved by the Saint
Louis University Institutional Animal Care and Use Committee.
HLA-A2 HHDII transgenic mice were provided by Ted Hansen
(Washington University) with permission from the Institut Pas-
teur and were bred and housed under pathogen-free conditions
throughout our studies.29 These mice are devoid of normal
murine MHC I expression, and express a chimeric HLA-A2 mol-
ecule consisting of human b2m and the a1–a2 domains of
Figure 1. Immunoinformatic strategy for identiﬁcation of HLA-A2-restricted CD8C T cell epitopes from T. cruzi. Genomic and proteomic data from Tri-
TrypDB25 was mined in order to identify HLA-restricted T cell epitopes in the highly conserved functional (enzymatically active) TS family (F-TS) and the
more diverse non-functional TS family (NF-TS), or within other antigens expressed in parasite life stages relevant for human immunity (Non-TS). Conser-
vation and epitope prediction analyses were performed using Conservatrix and EpiMatrix, respectively, in order to identify relatively conserved HLA-A2
binders in F-TS and NF-TS gene family members (A). Potentially secreted T. cruzi proteins shown to be expressed by mass spectrometry in amastigote
(AMA), insect-borne infectious metacyclic trypomastigote (MT) and blood form trypomastigote (BFT) equivalent life stages were identiﬁed and EpiMatrix
utilized to predict HLA-A2 binding peptides (Non-TS genes; B).
2324 Volume 11 Issue 9Human Vaccines & Immunotherapeutics
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HLA-A2.1 fused to the a3 and cytoplasmic domains of
H-2Db.29 In order to prepare dendritic cells (DC) for use in pep-
tide/DC vaccination experiments, 5£ 106 B16-Flt3L cells were i.
p injected into 3-month old female HLA-A2 transgenic mice to
induce expansion of immature DC as previously described.30
Two weeks later, DC were matured in vivo for 16–18 hours by
intravenous injection of LPS (2 mg/mouse). Spleens were isolated
and digested using collagenase and DNase, mechanically dis-
persed, processed to lyse red blood cells, and then CD11cC cells
were purified using magnetic beads following manufacturer
guidelines (Miltenyi biotec). Mature DC (mDC) were suspended
in complete DC media (2 parts fresh complete media plus 1 part
B16-Flt3L conditioned media) supplemented with 1,000 U/ml
GM-CSF, and pulsed with pools of F-TS, NF-TS, or Non-TS
predicted HLA-A2 binders (JPT Peptide Technologies) at 5 mg/
ml of each peptide for 2 hours. Mature DC were also pulsed
with the known I–Ab-restricted CD4C T cell epitope OVA323
339 to provide CD4
C T cell help for the development of CD8C
T cell responses. Mice were vaccinated twice, 2 weeks apart with
1 £ 106 peptide-pulsed mDC intravenously.
Four weeks following the final vaccination, individual pep-
tide-specific CD8C T cell responses were studied using IFN-g
ELISPOT assays.31 Briefly, splenic CD8C T cells were isolated
from control and peptide-pulsed DC vaccinated mice using Mil-
tenyi CD8 microbeads and added to IFN-g ELISPOT assays (1
£ 105 CD8C T cells/well; N D 2–3 mice/group). Na€ıve total
spleen cells were pulsed with individual peptides (5 mg/ml final
concentration) and used as stimulator cells in these ELISPOT
Figure 2. Immunogenicity of predicted HLA-A2-restricted T. cruzi epitopes. HLA-A2 transgenic mice were vaccinated twice, 2 weeks apart with mature
dendritic cells pulsed with functional TS (F-TS; A), Non-functional TS (NF-TS; B), or whole genome derived Non-TS peptide pools (C). One month later,
CD8C T cells were isolated from control DC or peptide-pool pulsed DC vaccinated mice and stimulated overnight with APCs pulsed with individual F-TS,
NF-TS, or Non-TS peptides in IFN-g ELISPOT assays. Shown are mean § SE from representative experiments expressed as IFN-g spot forming cells (SFC)
per million CD8C T cells above DMSO control. Asterisks denote immunogenic peptides deﬁned as responses greater than the mean C2 SE of all control
CD8C T cell responses.
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assays (3 £ 105 per well). After overnight co-culture, IFN-g ELI-
SPOT plates were developed and spots enumerated as previously
described.31 Shown in Figure 2 are results from these experi-
ments (background values subtracted). As expected, CD8C T
cells from mice vaccinated with control mDC did not respond to
the predicted HLA-A2-restricted T cell epitopes. In contrast,
many of the TS family and Non-TS predicted peptides elicited
responses in mice vaccinated with the dendritic cells pulsed with
peptides. The highly conserved functional TS family epitope
F-TS-2 elicited the strongest response of any peptide studied in
these assays (nearly 5,000 IFN-g SFC/million CD8C T cells;
Fig. 2A). Several responses were elicited by stimulation of T cells
from mice vaccinated with NF-TS peptides (5 of 6 NF-TS pepti-
des were immunogenic; Fig. 2B). In addition, 24 Non-TS epito-
pes were found to be HLA-A2-restricted CD8C T cell epitopes
(Fig. 1B). In total, we identified 30 HLA-A2-restricted CD8C T
cell epitopes using a novel approach involving genomic, proteo-
mic, and immunoinformatic analyses.
Previous studies aimed at CD8C T cell epitope discovery in
human-translatable models have focused on identifying T cell
epitopes from either single T. cruzi proteins (i.e., paraflegellar
rod proteins)32 or a small number of similar T. cruzi genes
within the TS superfamily33,34. Even though these proteins are
immunogenic in mice (and to some extent in humans), there
are concerns that developing vaccines targeting single proteins
may not contain sufficient epitopes for induction of immunity
in populations expressing diverse HLA alleles. Furthermore, it
has been postulated that T. cruzi has developed complicated
mechanisms to evade host cell immunity allowing for parasite
persistence. The TS superfamily with 1,430 gene members is
significantly overrepresented in the T. cruzi genome, however,
the complexity of the TS superfamily and immunodominance
patterns of specific TS CD8C T cell epitopes are not well
understood.20,24,35,36, The mechanism responsible for evolution
and expansion of the TS gene superfamily is not known. It has
been hypothesized that TS antigens may dampen overall immu-
nity through generation of altered peptide ligands, possibly con-
tributing to parasite persistence.37 However, we and others have
shown that TS is highly immunogenic in both mice and
humans, and TS vaccines induce potent immunity protective
against highly lethal parasite challenge in mice.14,15,22,23 While
there is little evidence to support the belief that the large TS
gene superfamily in T. cruzi evolved to evade host-cell mediated
immunity, generating immunity to a diverse group of proteins
using multi-epitope T cell targeted vaccines might prove to be a
sensible tactic to circumvent these hypothesized parasite persis-
tence strategies. We have utilized a novel approach to identify T
cell epitopes expressed by very diverse T. cruzi proteins. The
immunogenic epitope sequences from F-TS, NF-TS, and Non-
TS gene sets (shown in Fig. 2 and summarized in Table 1) are
encoded by genes with diverse functions. In our limited study,
we have identified T cell epitopes from enzymatically active as
well as more diverse non-functional TS gene family members (6
total conserved immunogenic TS superfamily epitopes). In addi-
tion, we have identified 24 immunogenic HLA-A2-restricted
epitopes from at least 13 different proteins using a modified
whole-genome epitope identification approach. Future studies
should investigate the relative levels of protective immunity
induced by vaccination with conserved F-TS, NF-TS, and
diverse Non-TS epitopes described here.
The HLA-A2 transgenic mice utilized in the studies above are
extremely susceptible to T. cruzi infection. The LD50 in this
mouse strain is less than 100 parasites, even when using relatively
non-virulent culture-derived metacyclic trypomastigotes (CMT)
challenges (not shown). Although we have been unable to induce
long-term survival in na€ıve HLA-A2 transgenic animals after
even low level parasite infection (preventing us from studying
infection-induced T cell responses to the above epitopes), vac-
cines encoding multiple CD8C T cell epitopes may be able to
confer some degree of protection in this mouse strain. Our efforts
to investigate protective immunity induced by multi-epitope
CD8C T cell targeted vaccines are ongoing. Liposomal-peptide
formulations, naked DNA vaccines, adjuvanted recombinant
protein, and attenuated viral vectors will be utilized to deliver
multi-epitope antigens expressed in a single open reading frame
(ORF). However, the optimal format, dose, and delivery routes
are not well established. Futures studies investigating protective
immunity induced by multi-epitope T cell targeted T. cruzi vac-
cines should give special attention to these details.
An HLA supertype is a group of genetically distinct HLA
alleles which share similar peptide binding properties. Nine
MHC class I supertypes have been identified.38 However,
>95% of individuals carry at least one HLA allele classified
Table 1. Immunogenic HLA-A2 -restricted CD8C T cell epitopes
Peptide ID Sequence Protein or Family
F-TS-2 EVYSLVFARL F-TS family
NF-TS-2 NVLLYNRPL NF-TS gene family
NF-TS-3 WLTDNTHIV NF-TS gene family
NF-TS-4 NTWRDEYLGV NF-TS gene family
NF-TS-5 KVGSDVFAV NF-TS gene family
NF-TS-6 RVFTSAVLL NF-TS gene family
Non-TS 2 VVMACLVPA cruzipain precurser
Non-TS 3 TLLFQVLLL surface protease GP63
Non-TS 4 RIGDVCAEV surface protease GP63
Non-TS 5 LLFQVLLLC surface protease GP63
Non-TS 6 YVVSLLADT histone H3
Non-TS 7 ALHSLVLFL hypothetical protein
Non-TS 8 AVIPSTFPL ATP synthase
Non-TS 9 SLFPFFFFV hypothetical protein
Non-TS 10 FLVDTIYSI citrate synthase
Non-TS 11 YLDAVFYPL pitrilysin-like metalloprotease
Non-TS 12 SLLCVISFI retrotransposon hot spot protein
Non-TS 13 ALLPWLLVL hypothetical protein
Non-TS 16 LMNDVWFSL heat shock protein 70
Non-TS 17 FLIFRFMVL hypothetical protein
Non-TS 18 FMACHTNPI hypothetical protein
Non-TS 19 MMHPFLCAL surface protein ToIT
Non-TS 24 SMNAGLYLL retrotransposon hot spot protein
Non-TS 25 AVFDSVYSV surface protease GP63
Non-TS 26 FLNQFGTRL hypothetical protein
Non-TS 27 SMQEYRHMV dynein light chain
Non-TS 29 SVVSVFFLL histone H3
Non-TS 31 QMLHNVASL pumilio/PUF RNA binding protein
Non-TS 32 MMMTGRVLL mucin-associated surface protein
Non-TS 33 TLMDFCPYI surface protease GP63
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into one of 6 most common MHC I supertypes. An estimated
50% of individuals from wide-ranging backgrounds express the
HLA-A2 supertype.19 In the current study we identified 30
diverse CD8C T cell epitopes restricted by this major supertype
(A2). The logical extension of our work described above is to
develop multi-epitope vaccines to induce protective immunity
in diverse human populations. Therefore, additional CD8C T
cell epitopes restricted by the other HLA supertypes need to be
identified. Similar strategies to those described in this report uti-
lizing EpiMatrix prediction of F-TS, NF-TS, and Non-TS gene
sets restricted by additional HLA supertypes should be
employed to identify additional T cell epitopes relevant for
diverse human populations. Long-term strategies to develop
either customized vaccines based on an individual’s HLA type
or a master vaccine encoding different T cell epitopes restricted
by all 6 major supertypes should be investigated. The optimal
number of epitopes needed to cover all populations, as well as
the optimal vaccine formulations (DNA, viral vector, adju-
vanted recombinant protein) must be carefully studied. Evi-
dence from animal studies suggests that the number of epitopes
required for full protection is a small and definable subset (less
than 50) [39,40]; thus, achieving a payload of 50–100 epitopes
that provide broad coverage of human genetic backgrounds may
be sufficient to provide protection.
It is well established that optimal memory CD8C T cell
responses are generated in the presence of robust CD4C T cell
help.14 CD4C T cells are critical for the development of protec-
tive immunity against T. cruzi infection.12,14 When normally
protective T. cruzi vaccines are depleted of CD4C T cell epitope
regions they lose their protective capacities.14 Thus, new T cell-
based T. cruzi vaccines should include immunogenic CD4C T
cell epitopes to help drive effective CD8C T cell responses.
MHC class II epitope prediction algorithms have been shown to
be accurate, and more recently tools have been developed to iden-
tify clusters of pan DR-restricted class II epitopes.27,28 For exam-
ple, matrix-based epitope prediction algorithms have been
utilized to identify conserved variola/vaccinia CD4C T cell epito-
pes that when formulated as multi-epitope vaccines were able to
confer protection against lethal vaccinia challenges in humanized
mice.28,41 A similar strategy should be utilized to identify pro-
miscuous CD4C T cell epitopes (or T cell epitope clusters)
within the F-TS, NF-TS, and Non-TS gene sets described in this
report. Exclusion of epitopes that are highly cross-conserved at
the human TCR face, and may be tolerogenic, should also be
taken into consideration.42
Additionally, antigen-specific B cells have been shown to play a
protective role in T. cruzi infection as both producers of lytic anti-
bodies for extracellular parasites reducing overall parasite burden
and as antigen presenting cells. Furthermore, we have recently
shown that T. cruzi specific B cells producing potent antibody
responses can help prevent CD8C T cell exhaustion.10 Recent
efforts by several groups utilizing overlapping peptide arrays or
high-throughput bioinformatic approaches have resulted in the
identification of specific antibody epitopes in several
T. cruzi genes.43-45 A 3-tiered approach focused on the inclusion of
CD4C T helper epitopes, CD8C T cell epitopes, and B cell epito-
pes should be investigated for use as both prophylactic and thera-
peutic vaccines for the prevention and treatment of Chagas disease.
The results presented here represent the first large-scale immu-
noinformatics driven-effort to identify CD8C T cell epitopes
from diverse T. cruzi gene sets relevant for human infection.
Many previous attempts aimed at identifying immunogenic
CD8C T cell epitopes have utilized standard laboratory mouse
strains expressing murine MHC.14,46 While results from these
types of studies have helped elucidate much of what we know
today about immunity to T. cruzi infection (including mecha-
nisms of protection), many of the epitopes will not be presented
by HLA to human T cells. Here, we have utilized a multifaceted
approach to identify parasite proteins and their encoded T cell
epitopes restricted by human MHC, specifically HLA-A2 which
is expressed by nearly half of the human population. Thus, the
CD8C T cell targets identified in this work are highly relevant
for the development of effective vaccines to protect humans at
risk of Chagas disease.
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